This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.
by Arpita Dutt
Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.
Mallinckrodt's MNK-1411 Gets Orphan Drug Status for DMD
by Zacks Equity Research
Mallinckrodt plc (MNK) announced that the FDA has granted orphan drug designation to its pipeline candidate - MNK-1411, which is being evaluated for the treatment of Duchenne muscular dystrophy (DMD).
Lilly Settles Patent Litigation on Cialis with Generic Firms
by Zacks Equity Research
Eli Lilly & Company (LLY) announced that it has entered into an agreement with generic companies to settle a patent relating to its erectile dysfunction drug Cialis (tadalafil).
Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform
by Zacks Equity Research
We issued an updated research report Endocyte, Inc. (ECYT) on Jul 12.
Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth
by Zacks Equity Research
On Jul 11, Alnylam Pharmaceuticals Inc. (ALNY) was upgraded to a Zacks Rank #2 (Buy).
Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.
Sanofi to Buy Vaccine Biotech Protein Sciences for $650M
by Zacks Equity Research
Sanofi (SNY), on Monday, announced plans to buy a Meriden, CT-based private vaccine biotech, Protein Sciences for an upfront payment of $650 million.
Are Medicines Company's Key Drugs Set for Growth in 2017?
by Zacks Equity Research
On Jul 7, 2017, we issued an updated report on The Medicines Company (MDCO).
Alnylam Commences Phase III Study for Hemophilia Candidate
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) announced that it has commenced phase III ATLAS study for its candidate fitusiran.
Endo (ENDP) to Remove Opioid Pain Drug Opana ER from Market
by Zacks Equity Research
Endo International plc (ENDP) recently announced that it will withdraw opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA's request in June.
Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff
by Zacks Equity Research
Both stocks carry a Zacks Rank #2 (Buy).
ProQR's Usher Syndrome Candidate Gets Orphan Drug Status
by Zacks Equity Research
ProQR Therapeutics N.V. (PRQR) announced that its key pipeline candidate, QRX-411, has been granted orphan drug designation by the FDA and European Medicines Agency (EMA) for the treatment of retinitis pigmentosa.
Sucampo (SCMP) Remains Focused on Amitza Label Expansion
by Zacks Equity Research
We issued an updated report on Sucampo Pharmaceuticals, Inc. (SCMP) on July 4.
AMAG Pharmaceuticals Focuses on Product Development & Buyouts
by Zacks Equity Research
We issued an updated report on AMAG Pharmaceuticals, Inc. (AMAG) on Jul 4.
Pfizer's (PFE) Leukemia Candidate Receives Approval in EU
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its leukemia candidate, Besponsa, has been approved by the European Commission.
The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva
Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US
by Zacks Equity Research
Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.
Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises
by Arpita Dutt
Merck's (MRK) results on its CETP inhibitor took the investment community by surprise while Sanofi gained EU approval for its rheumatoid arthritis (RA) drug.
Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA has accepted its New Drug Application for Plenvu.
Robust 1H for Pharma/Biotech Sector, 3 Big Stocks to Buy
by Zacks Equity Research
The pharma and biotech industry has been blessed with good health in the first half of the year.
Seattle Genetics (SGEN) Reports Positive Data for Adcetris
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study, ECHLEON 1 study.
Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.
Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion
by Zacks Equity Research
Amgen announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion recommending marketing approval of a pediatric formulation of Mimpara for the treatment of secondary hyperparathyroidism
Regeneron (REGN) Stock on Fire: What's Behind the Surge?
by Zacks Equity Research
Shares of Regeneron Pharmaceuticals, Inc. (REGN) have moved up 14.8% over the last 30 days.
Why You Should Add Novo Nordisk Stock to Your Portfolio
by Zacks Equity Research
Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.